Your Best Stock
Stocks › Infectious Disease › TMO

Thermo Fisher Scientific TMO

US equityMarket cap rank #59Diagnostics & ResearchInfectious DiseaseRobotics
$670.67
+$5.37 (+0.81%)
Market open · Sep 24, 1:10 pm ET
After hours $665.30 0.00%
Open$661.08
Prev close$665.30
Day range$655.95 – $681.55
Volume960.7K
Market cap$247.98B
P/E (TTM)36.1
Dividend yield0.27%

Earnings

Average move on report day±4.0%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+9.1%
Worst reaction-9.2%

Stock move on the day after each report

-5.5%2023/Q3-5.0%2023/Q4+0.5%2024/Q1+4.1%2024/Q2-1.7%2024/Q3+6.8%2024/Q4-0.7%2025/Q1+9.1%2025/Q2+1.7%2025/Q3-2.6%2025/Q4-9.2%2026/Q1+8.7%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q223 Jul 2026Pre Market±29.8%+8.71%Within range
2026/Q123 Apr 2026Pre Market±23.7%-9.20%Within range
2025/Q429 Jan 2026Pre Market±25.8%-2.61%Within range
2025/Q322 Oct 2025Pre Market±24.5%+1.65%Within range
2025/Q223 Jul 2025Pre Market±22.2%+9.14%Within range
2025/Q123 Apr 2025Pre Market±24.1%-0.71%Within range
2024/Q430 Jan 2025Pre Market±26.8%+6.78%Within range
2024/Q323 Oct 2024Pre Market±25.1%-1.69%Within range
2024/Q224 Jul 2024Pre Market±22.2%+4.07%Within range
2024/Q124 Apr 2024Pre Market±25.4%+0.49%Within range
2023/Q431 Jan 2024Pre Market±21.5%-4.96%Within range
2023/Q325 Oct 2023Pre Market±19.5%-5.47%Within range
2023/Q226 Jul 2023Pre Market±21.5%+0.61%Within range
2023/Q126 Apr 2023Pre Market±23.4%-2.78%Within range
2022/Q41 Feb 2023Pre Market±23.7%+2.99%Within range
2022/Q326 Oct 2022Pre Market±22.6%-2.26%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Laboratory Products and Biopharma Services$6.69B 53.3%
  • Life Sciences Solutions$2.82B 22.4%
  • Analytical Instruments$1.85B 14.7%
  • Specialty Diagnostics$1.21B 9.6%

Fundamentals

Full statements →

Latest reported quarter: Q2, ended Jun 2026

Revenue$11.99B+10.5% YoY
Operating profit$2.19B+14.0% YoY
Net profit$1.74B+7.6% YoY
Diluted EPS$4.68+9.3% YoY
Free cash flow$1.68B+51.6% YoY
Operating cash flow$2.13B

Revenue, last 8 quarters

$10.6BSep '24$11.4BDec '24$10.4BMar '25$10.9BJun '25$11.1BSep '25$12.2BDec '25$11.0BMar '26$12.0BJun '26

Net profit, last 8 quarters

$1.6BSep '24$1.8BDec '24$1.5BMar '25$1.6BJun '25$1.6BSep '25$2.0BDec '25$1.7BMar '26$1.7BJun '26

Profitability & balance sheet

Gross margin40.8%
Operating margin18.3%
Net margin15.0%
Return on equity13.5%
Return on assets6.5%
Return on invested capital8.2%
Current ratio1.55
Liabilities / assets53.3%
Cash & investments$4.06B
Total debt$42.55B
Net cash (debt)-$38.49B
Free cash flow / sales15.8%
Scroll to Top